GlassScriptPhysician profile
Turab Mohammed
NPI 1730743568
$6,798.53
in general payments reported to CMS, 2019-2025
15 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.24 · 2023: $379 · 2024: $5,990 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,841 · Food and Beverage: $1,447 · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,840.72 |
| Food and Beverage | $1,447.23 |
| Education | $426.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $4,464.76 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $639.75 | 2024 | Calquence |
| Gilead Sciences, INC. | $336.74 | 2023-2024 | Trodelvy |
| Lilly USA, LLC | $293.68 | 2024 | Jaypirca |
| Seagen INC. | $224.95 | 2023-2024 | Adcetris |
| Astellas Pharma US INC | $154.98 | 2024 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | Ultomiris |
| Btg International INC. | $121.85 | 2025 | Voraxaze |
| Recordati_rare_diseases_inc. | $107.36 | 2024 | Sylvant |
| Pfizer INC. | $106.45 | 2022-2023 | |
| Incyte Corporation | $102.00 | 2025 | Niktimvo |
| Merck Sharp & Dohme LLC | $46.95 | 2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $40.72 | 2025 | Blenrep, Ojjaara |
| Tempus Ai, INC | $18.59 | 2025 | Xt Cdx |
| Daiichi Sankyo INC. | $14.75 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Turab Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.